Generic placeholder image

Mini-Reviews in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1389-5575
ISSN (Online): 1875-5607

Inhibitors of Platelets Glycoprotein IIb / IIIa (GP IIb / IIIa) Receptor: Rationale for their Use in Clinical Cardiology

Author(s): M. L. Rossi and D. Zavalloni

Volume 4, Issue 7, 2004

Page: [703 - 709] Pages: 7

DOI: 10.2174/1389557043403666

Price: $65

Abstract

The glycoprotein IIb / IIIa (GP IIb / IIIa) receptor is the most important receptor involved in platelet aggregation. A stable GP IIb / IIIa inhibition is required when a massive platelet activation triggers thrombosis. Three GP IIb / IIIa inhibitors are currently approved for clinical use: abciximab, tirofiban and integrilin. Their different pharmacodynamic and pharmacokinetic properties reflect a different efficacy in platelet inhibition.

Keywords: platelet aggregation inhibitors, glycoprotein, acute coronary syndromes, atherosclerotic plaque, percutaneous coronary intervention

Next »

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy